| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Experimental Hematology and Hematopoiesis Section, and
Hematopathology Section, Cleveland Clinic Foundation, Cleveland, OH 44195; and
National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892
Large granular lymphocytic (LGL) leukemia is a clonal lymphoproliferative disorder of CTL associated with cytopenias resulting from an immune and cytokine attack on hemopoietic progenitor cells. Extreme clonality of CTL expansions seen in LGL leukemia makes it an ideal model to study the role of the T cell repertoire in other less-polarized immune-mediated disorders. Complementarity-determining region 3 (CDR3) of the TCR is a unique Ag-specific region that can serve as a molecular marker, or clonotype, of the disease-specific T cells. We studied the variable portion of the 
-chain spectrum in a cohort of LGL leukemia patients. The CDR3 sequences were determined for the immunodominant clones and used to design clonotype-specific primers. By direct and semi-nested amplification, clonotype amplicons were found to be shared by multiple patients and controls. Analysis of the generated sequences demonstrated that the original clonotypes are rarely encountered in normal control samples; however, high levels of homology were found in both controls and patients. Clonotypes derived from individual LGL patients can be used as tumor markers for the malignant clone. More generally, clonotypic analysis and comparison of the variable portion of the -chain CDR3-specific sequences from a large number of patients may lead to better subclassification of not only LGL but also other immune-mediated disorders.
This article has been cited by other articles:
|
|
 |
|
  M. W. Wlodarski, Z. Nearman, A. Jankowska, N. Babel, J. Powers, P. Leahy, H.-D. Volk, and J. P. Maciejewski Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia J. Leukoc. Biol., March 1, 2008; 83(3): 589 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. O'Keefe, L. Gondek, R. Davis, E. Kuczkowski, R. M. Sobecks, A. Rodriguez, Y. Narvaez, Z. McIver, R. Tuthill, M. Laughlin, et al. Molecular Analysis of Alloreactive CTL Post-Hemopoietic Stem Cell Transplantation J. Immunol., August 1, 2007; 179(3): 2013 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Garrido, F. Ruiz-Cabello, P. Barcena, Y. Sandberg, J. Canton, M. Lima, A. Balanzategui, M. Gonzalez, M. A. Lopez-Nevot, A. W. Langerak, et al. Monoclonal TCR-V 13.1+/CD4+/NKa+/CD8 /+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin Blood, June 1, 2007; 109(11): 4890 - 4898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Wlodarski, L. P. Gondek, Z. P. Nearman, M. Plasilova, M. Kalaycio, E. D. Hsi, and J. P. Maciejewski Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome Blood, October 15, 2006; 108(8): 2632 - 2641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Sokol and T. P. Loughran Jr. Large granular lymphocyte leukemia. Oncologist, March 1, 2006; 11(3): 263 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. W. Wlodarski, C. O'Keefe, E. C. Howe, A. M. Risitano, A. Rodriguez, I. Warshawsky, T. P. Loughran Jr, and J. P. Maciejewski Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia Blood, October 15, 2005; 106(8): 2769 - 2780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Berliner, M. Horwitz, and T. P. Loughran Jr. Congenital and Acquired Neutropenia Hematology, January 1, 2004; 2004(1): 63 - 79. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
